3.5 g/day) and hypoalbuminemia typically have a progressive course to end stage renal disease. It appears that primary FSGS is responded to prednisone at a dose of 1 mg/kg per day (maximum dose 60 to 80 mg/day) in 40 to 80 % of patients, however prolonged glucocorticoid therapy for a minimum of 12 to 16 weeks is generally required to induce remission among these patients. For the treatment of steroid-resistant or relapsing disease, cyclosporine is most commonly used at a dose of approximately 2 to 4 mg/kg per day (given in two divided doses) in conjunction with low dose of prednisone (maximum 15 mg/day). In addition, other agents, including cyclophosphamide and mycophenolatemofetile have also been tried among steroid-resistant or relapsing disease with various degrees of response.]]>
p. 645−653
2252-0619
Vol.12/No.6
p. 735−739
2252-0619
Vol.12/No.6
p. 685−692
2252-0619
Vol.12/No.6
p. 693−703
2252-0619
Vol.12/No.6
p. 655−663
2252-0619
Vol.12/No.6
10Í109/L, peripheral blood monocyte count > 1 Í109 /L, bone marrow blasts < 20% with no Philadelphia chromosome was identified. Fetal haemoglobin (HbF) was within the normal range. The patient responded completely to chemotherapy, but the disease recurred later. Bone marrow transplantation (BMT) was carried out but the patient expired due to infection complications associated with transplantation..
Conclusion: Although chemotherapy protocols, which induce maturation and differentiation, are used as a temporary treatment, BMT is the definite treatment for JMML. BMT is the only treatment which able to cure JMML, but the high relapse rate is of great concern and it may be unavailable anywhere, and patient selection for this method need to be carefully undertaken. Recent advances in diagnosis and treatment of JMML will be discussed here.]]>
p. 441−450
2252-0619
Vol.12/No.6
p. 705−714
2252-0619
Vol.12/No.6
p. 723−734
2252-0619
Vol.12/No.6
p. 677−684
2252-0619
Vol.12/No.6
p. 715−721
2252-0619
Vol.12/No.6
p. 629−643
2252-0619
Vol.12/No.6
p. 665−676
2252-0619
Vol.12/No.6